

Jo Morrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7181420/publications.pdf>

Version: 2024-02-01

62
papers

1,639
citations

361296

20
h-index

360920

35
g-index

70
all docs

70
docs citations

70
times ranked

2209
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphadenectomy for the management of endometrial cancer. The Cochrane Library, 2017, 2017, CD007585.	1.5	173
2	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. The Cochrane Library, 2012, , CD005343.	1.5	112
3	Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. European Journal of Immunology, 1992, 22, 903-907.	1.6	110
4	Lymphadenectomy for the management of endometrial cancer. , 2010, , CD007585.		96
5	Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. Molecular Therapy, 2008, 16, 244-251.	3.7	81
6	Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. Gynecologic Oncology, 2016, 143, 287-293.	0.6	77
7	A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells. Science, 1992, 257, 964-967.	6.0	76
8	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 213, 123-139.	0.5	64
9	Lymphadenectomy for the management of endometrial cancer. , 2015, , CD007585.		61
10	Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. Journal of Gene Medicine, 2008, 10, 280-289.	1.4	52
11	The emerging epidemic of endometrial cancer: Time to take action. , 2014, , ED000095.		50
12	British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 270, 50-89.	0.5	46
13	Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. British Journal of Surgery, 2021, 108, 88-96.	0.1	45
14	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Library, 2015, , CD007929.	1.5	41
15	Cesarean section on demand. Seminars in Perinatology, 2003, 27, 20-33.	1.1	38
16	Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer. Human Gene Therapy, 2009, 20, 239-251.	1.4	37
17	British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 252, 502-525.	0.5	36
18	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. , 2007, , CD005343.		34

#	ARTICLE	IF	CITATIONS
19	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. The Cochrane Library, 2019, 2019, .	1.5	34
20	British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU). International Journal of Gynecological Cancer, 2020, 30, 695-700.	1.2	34
21	Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. The Cochrane Library, 2016, 2016, CD006910.	1.5	30
22	Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. The Cochrane Library, 2021, 2, CD005343.	1.5	29
23	Angiogenesis inhibitors for the treatment of ovarian cancer. The Cochrane Library, 2011, , CD007930.	1.5	25
24	Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. The Cochrane Library, 2021, 2021, CD005343.	1.5	25
25	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Library, 2022, 2022, CD007929.	1.5	22
26	Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. The Cochrane Library, 2021, 2021, CD013021.	1.5	19
27	Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1122-1132.	1.1	18
28	'Two week wait' standards for suspected gynaecological malignancy. On target, but missing the point?. The Journal of the British Menopause Society, 2003, 9, 170-172.	1.3	16
29	Epidermal growth factor receptor blockers for the treatment of ovarian cancer. The Cochrane Library, 2011, , CD007927.	1.5	16
30	Epidermal growth factor receptor blockers for the treatment of ovarian cancer. The Cochrane Library, 2018, 2018, CD007927.	1.5	16
31	Sentinel lymph node consensus document of the British Gynaecological Cancer Society for endometrial, vulvar, and cervical cancers. International Journal of Gynecological Cancer, 2019, 29, 1348-1350.	1.2	13
32	Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. , 2013, , CD010482.		12
33	Patient-initiated follow-up after treatment for low risk endometrial cancer: a prospective audit of outcomes and cost benefits. International Journal of Gynecological Cancer, 2020, 30, 1177-1182.	1.2	11
34	Advances in the understanding and treatment of ovarian cancer. The Journal of the British Menopause Society, 2005, 11, 66-71.	1.3	10
35	Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: Implications for ovarian cancer therapy. Virology, 2013, 447, 74-83.	1.1	9
36	DNA-repair pathway inhibitors for the treatment of ovarian cancer. , 2010, , CD007929.		8

#	ARTICLE	IF	CITATIONS
37	Lymphadenectomy for Treatment of Early-Stage Endometrial Cancer. JAMA Oncology, 2017, 3, 117.	3.4	7
38	British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. International Journal of Gynecological Cancer, 2022, 32, 9-14.	1.2	7
39	Relationship between vulvar symptoms and incidence of vulvar cancer in women referred to a rapid access clinic. International Journal of Gynecology and Obstetrics, 2019, 145, 283-286.	1.0	6
40	Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. The Cochrane Library, 2018, , .	1.5	5
41	Management of Malignant Vulval Melanoma: A Retrospective Case Series and Review of the Literature. Journal of Lower Genital Tract Disease, 2020, 24, 272-276.	0.9	5
42	Audit of the care of women requesting induced abortion. Journal of Obstetrics and Gynaecology, 2003, 23, 521-524.	0.4	4
43	Vertical transmission of human immunodeficiency virus. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 5-12.	0.2	3
44	Borderline ovarian tumours: balancing risks of recurrence over decades. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 945-945.	1.1	3
45	Junior doctor-led quality improvement project to improve safety and visibility of an interspecialty referral system. BMJ Open Quality, 2021, 10, e001323.	0.4	3
46	Avoiding and managing complications during gynaecological surgery. Obstetrics, Gynaecology and Reproductive Medicine, 2007, 17, 105-111.	0.1	2
47	HPV vaccination: balancing facts. The Cochrane Library, 2018, 6, ED000126.	1.5	2
48	Improving Outcomes in Gynaecological Cancer: The Benefits of Subspecialisation. , 2012, , ED000040.		2
49	Improving the uptake of cervical screening in pregnant and recently postnatal women: a quality improvement project. BMJ Open Quality, 2022, 11, e001709.	0.4	2
50	Key clinical trials in gynaecological oncology. European Journal of Surgical Oncology, 2006, 32, 887-891.	0.5	1
51	Epidermal growth factor receptor blockers for the treatment of ovarian cancer. , 2009, , .		1
52	Endometrial cancer follow up; finding the confidence to let go?. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1715-1715.	1.1	1
53	Small cell neuroendocrine tumour of the cervix in pregnancy: the importance of multidisciplinary management. BMJ Case Reports, 2021, 14, e237058.	0.2	1
54	Audit of anti-D immunoglobulin administration to pregnant Rhesus D negative women following sensitising events. Journal of Obstetrics and Gynaecology, 2000, 20, 371-373.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Atlas of Pelvic Anatomy and Gynecologic Surgery. The Obstetrician and Gynaecologist, 2003, 5, 242-243.	0.2	0
56	Current management of ovarian carcinoma. Therapy: Open Access in Clinical Medicine, 2005, 2, 275-286.	0.2	0
57	Finding time to make the right decision: using frozen section to inform intra-operative management of suspicious ovarian masses. , 2016, 3, ED000109.		0
58	Spotlight on gynaecological cancer. The Obstetrician and Gynaecologist, 2017, 19, 197-197.	0.2	0
59	Gynecological cancer. , 2007, , 169-180.		0
60	Spotlight on gynaecological cancer. The Obstetrician and Gynaecologist, 2022, 24, 88-89.	0.2	0
61	Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination. The Cochrane Library, 2022, 2022, .	1.5	0
62	Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	0